BrainStorm Cell Therapeutics Inc. $(BCLI)$ has announced a strategic partnership with Minaris Advanced Therapies for the manufacturing of its experimental therapy, NurOwn®, in preparation for a Phase 3b clinical trial aimed at treating amyotrophic lateral sclerosis (ALS). The collaboration involves a Letter of Intent for technology transfer and clinical trial manufacturing at Minaris' facility in Allendale, New Jersey. This partnership aims to enhance BrainStorm's manufacturing capabilities in the U.S. and is part of a broader strategy to support the upcoming clinical trial. Additionally, BrainStorm's collaboration with Pluri Inc. in Israel will contribute to the production of clinical trial materials. BrainStorm emphasizes its commitment to advancing the clinical development of NurOwn® through these strategic relationships.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.